KOVALTRY® Ordering Information

KOVALTRY has a permanent, unique J-code that can be used to identify KOVALTRY on healthcare claims forms.

Healthcare Common Procedure Coding System(HCPCS) Code Description
J7211 Injection, factor viii, (antihemophilic factor, recombinant), (Kovaltry), 1 i.u.
Download KOVALTRY® Billing and Coding Guide for additional coding information and sample claim forms.

For reimbursement support, coverage, and financial solutions, reach out to Access Services by BayerTM at 1-800-288-8374 8:00 AM-8:00 PM (ET) Monday to Friday.

250 IU*Billing NDC#0026-3821-25Diluent (mL)2.5
500 IU*Billing NDC#0026-3822-25Diluent (mL)2.5
1000 IU*Billing NDC#0026-3824-25Diluent (mL)2.5
2000 IU*Billing NDC#0026-3826-50Diluent (mL)5.0
3000 IU*Billing NDC#0026-3828-50Diluent (mL)5.0


KOVALTRY® Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

On-demand treatment and control of bleeding episodes

Perioperative management of bleeding

Routine prophylaxis to reduce the frequency of bleeding episodes

KOVALTRY is not indicated for the treatment of von Willebrand disease.


KOVALTRY is contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins.

Hypersensitivity reactions, including anaphylaxis, are possible with KOVALTRY. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOVALTRY if symptoms occur and seek immediate emergency treatment.

KOVALTRY may contain trace amounts of mouse and hamster proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins.

Neutralizing antibody (inhibitor) formation has occurred following administration of KOVALTRY. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all Factor VIII products. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled as expected with administered dose, suspect the presence of an inhibitor.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

The most frequently reported adverse reactions in clinical trials (≥3%) were inhibitors in previously untreated patients (PUPs)/minimally treated patients (MTPs), and headache, pyrexia, and pruritus.

For additional important risk and use information, please see full Prescribing Information.

You are encouraged to report negative side effects or quality complaints of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

© 2021 Bayer.   All rights reserved.
Bayer, the Bayer Cross, and KOVALTRY are registered trademarks of Bayer.
Access Services by Bayer is a trademark of Bayer.
Advate is a registered trademark of Baxalta Incorporated, a wholly owned, indirect subsidiary of Shire plc.

Site Last Modified 02/2021